Daily Roundup

NEU.ASX SDV.ASX MYE.ASX EQR.ASX LNW.ASX

Neuren Pharmaceuticals is riding high on strong momentum for its flagship drug DAYBUE. The company reported record Q2 sales of US$125 million, marking a 30% jump from the same quarter last year. The real driver here is DAYBUE STIX, a new powder formulation that's resonating with patients—by the end of Q2, roughly 40% of US patients were already using it. Looking ahead, Neuren expects to benefit from a European launch anticipated in Q4 2026, and Japan trial results should arrive sometime between September and November. The company also locked in upgraded royalty guidance for the full year, with Q2 royalty income hitting US$12.9 million.

SciDev is making its first real push into the data centre space. The company has secured initial contracts with two of Australia's largest hyperscale data centre operators, covering design, consulting, and embedded engineering services. These deals are expected to generate around $0.5 million in revenue during the first half of FY27, with room for expansion down the track.

Mastermyne Group (trading as Metarock) has landed a substantial new mining services contract with GM3 for the Dendrobium underground coal mine in New South Wales. The initial two-year term is worth an estimated $85 million in gross revenues, with two additional two-year extension options that could push the total value to $255 million over six years. The contract will create more than 140 new roles and builds on Mastermyne's existing work at the site.

EQ Resources, a global tungsten producer, hit a revenue record of A$51 million in July 2026. The company's consolidated production jumped 36% compared to June, reaching 14,255 mtu, and it achieved a record average realised price of US$2,386 per mtu. The Barruecopardo site was particularly strong, posting its highest monthly production since December 2025 with a 48% increase.

Light & Wonder delivered a solid quarter with net income climbing 26% to $120 million and consolidated AEBITDA rising 9% to $383 million. Revenue edged up 2% year-over-year to $828 million, fuelled by growth in Gaming operations and iGaming, which posted a 14% increase. Recurring revenue grew 6% to $580 million. The company also returned $134 million to shareholders through buybacks and maintained its full-year outlook, expecting mid- to high-single-digit AEBITDA growth. Management remains focused on reducing net debt leverage below 3.0x during the first half of 2027.